Skip to main content

Table 2 Thrombotic and ischemic complications depending on anticoagulant treatment

From: Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study

  All patients (n = 179) Prophylactic group (n = 108) Therapeutic group (n = 71) Univariable analysis Multivariable analysis
OR [95% CI] p OR [95% CI] p
Thrombo-embolic complications—n (%) 57 (31.8) 42 (38.9) 15 (21.1) 0.42 [0.20–0.88] 0.01 0.38 [0.14–0.94] 0.04
Pulmonary embolisms – n (%) 25 (14.0) 22 (20.4) 3 (4.2) 0.17 [0.03–0.61] < 0.01 0.19 [0.03–0.81] 0.04
Deep vein thrombosis—n (%) 11 (6.1) 10 (9.3) 1 (1.4) 0.13 [0–1.39] 0.18 0.13 [0.01–0.89] 0.04
Cerebral ischemic attack—n (%) 6 (3.4) 6 (5.6) 0 0 [0–1.27] 0.09 0.06 [0–0.68] 0.02
RRT filter/thrombosis—n (%) 32 (17.9) 19 (17.6) 13 (16.7) 0.97 [0;41–2.24] 0.94 1.04 [0.34–3.11] 0.95
Nb of RRT filter per day of RRT—median, IQR 3.0 [1.0; 6.8] 3.0 [2.0; 7.0] 2.0 [1.0; 5.0] / 0.52 / /
  1. CI confidence interval, IQR interquartile range, OR odds ratio, RRT renal replacement therapy